A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2
385
about 6.4 years
18+
14 sites in CA, CO, IA +8
What this study is about
This trial is testing a treatment called JNJ-90014496 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The treatment is an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both CD19 and CD20.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive JNJ-90014496
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability], Phase 2: Overall Response (OR) As Assessed by Independent Review Committee (IRC)
Secondary: Change From Baseline of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Symptom Score, Phase 1b: Duration of Response (DOR), Phase 1b: Overall Response (OR), Phase 1b: Pharmacokinetic Evaluation of Prizlo-Cel, Phase 2: Area Under the Blood Concentration Time Curve (AUC) for Prizlo-Cel, Phase 2: Complete Response (CR), Phase 2: Duration of Response (DOR), Phase 2: Maximum Observed Blood Concentration (Cmax) for Prizlo-Cel
Oncology